CDx

Albuquerque, NM, June 30, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the launch of Prostate Macrodissect AI, a clinically validated algorithm designed to automate and quantify tumor content in FFPE prostate tissue specimens. Prostate Macrodissect AI is designed to operate in concert with Indica Labs’ broader HALO Clinical AI suite, enabling laboratories to build end-to-end AI-powered prostate cancer workflows from automated tumor detection and Gleason grading assistance through to optimized macrodissection and genomic test preparation within a single, validated digital pathology platform.

Albuquerque, NM, May 27, 2026 – Indica Labs, the global leader in AI-powered digital pathology solutions, today announced a major expansion of its companion diagnostics (CDx) capabilities, positioning the company at the forefront of precision medicine innovation ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.